Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT01787487 trial: what clinicians have said so far
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT01787487 ↗
- Completed
- M.D. Anderson Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT01787487 (ruxolitinib plus azacitidine in myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT01787487 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 YouTube videos, typically up to 9 once built | |
| 1 post on X, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative Neoplasm
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Myelofibrosis Transformation in Essential Thrombocythemia; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis
- Interventions
- Azacitidine; Laboratory Biomarker Analysis; Ruxolitinib Phosphate
- Arms
- Arm I (MF patients) · Experimental
- Arm II (MDS/MPN patients) · Experimental
- Enrollment
- 121
- Primary outcomes
- Objective response rate (complete remission, partial remission, clinical improvement) in patients with myelofibrosis
- Objective response rate (complete remission, partial remission, and hematologic improvement) in patients with myelodysplastic syndromes/myeloproliferative neoplasms
- Sponsor
- M.D. Anderson Cancer Center with National Cancer Institute (NCI)
- Start
- Mar 13, 2013
- Primary completion
- Jan 20, 2026
- Results posted
- No
- Registry record
- NCT01787487 · updated Mar 31, 2026
Publications
linked from the registry- Arora S, Senapati J, Deshmukh I, Bose P, Masarova L, Loghavi S, Wang X, Nogueras-Gonzalez G, Montalban-Bravo G, Borthakur G, DiNardo CD, Kadia T, Zhou L, Saenz D, Halim H, Alvarado Y, Ohanian M, Takahashi K, Short NJ, Jabbour E, Ravandi F, Garcia-Manero G, Pemmaraju N, Daver NG. Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms. J Hematol Oncol. 2026 Jun 16. doi: 10.1186/s13045-026-01813-7. Online ahead of print. PubMed 42304430
- Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 Oct 18;132(16):1664-1674. doi: 10.1182/blood-2018-04-846626. Epub 2018 Sep 5. PubMed 30185431
- Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 Feb;93(2):277-285. doi: 10.1002/ajh.24972. Epub 2017 Nov 27. PubMed 29134664